胶质母细胞瘤CXCR4表达与[68Ga]Ga-Pentixafor PET及[177Lu]Lu-Pentixather治疗潜力
该研究通过mRNA数据库和免疫组化分析胶质母细胞瘤CXCR4表达,并初步探索[68Ga]Ga-Pentixafor PET。结果显示CXCR4表达存在较大瘤间和瘤内异质性,正常脑组织阴性,且与IDH/MGMT状态及生存无显著相关;7例复发患者PET与离体染色结果不能直接对应。提示高表达患者可能适合[177Lu]Lu-Pentixather靶向治疗,但需谨慎解读离体表达与PET摄取的关系。
要点
- 胶质母细胞瘤CXCR4表达异质性大,部分肿瘤高表达,正常脑组织阴性。
- CXCR4表达与IDH或MGMT状态及生存无显著相关性。
- 离体CXCR4染色不能直接等同于[68Ga]Ga-Pentixafor PET摄取。
核心结论
- 免疫组化显示部分胶质母细胞瘤高表达CXCR4,且存在较大瘤间和瘤内变异。
- 离体CXCR4表达不能直接推及[68Ga]Ga-Pentixafor PET摄取。
- 若[68Ga]Ga-Pentixafor PET能识别高CXCR4表达,患者未来可能适合[177Lu]Lu-Pentixather靶向核素治疗。
研究设计与样本
- 研究利用R2基因组学平台分析CXCR4 mRNA表达,并对胶质母细胞瘤组织芯片进行CXCR4免疫组化染色评分。
- 共分析191例胶质母细胞瘤的426个组织芯,并收集IDH和MGMT启动子甲基化状态及临床信息。
- 7例复发胶质母细胞瘤患者接受[68Ga]Ga-Pentixafor PET,并对残留切除组织进行CXCR4染色。
主要发现
- 两个大型mRNA数据集(N=284;N=540)被评估。
- 其余330个组织芯(163例肿瘤)显示较大的瘤间和瘤内CXCR4表达变异,7例试点患者的切除组织亦见类似变异。
- mRNA和免疫组化均显示正常脑组织CXCR4阴性,且CXCR4表达与IDH或MGMT状态及生存无显著相关性。
关键数值与推荐
- 免疫组化评分将肿瘤细胞CXCR4染色分为阴性、强且广泛染色及异质性表达。
- mRNA数据集样本量分别为N=284和N=540。
- 组织芯片分析涵盖191例胶质母细胞瘤的426个组织芯。
临床怎么用
- 对胶质母细胞瘤患者,可考虑[68Ga]Ga-Pentixafor PET评估CXCR4表达以筛选潜在靶向治疗 candidates。
- 离体CXCR4免疫组化结果不宜直接用于预测PET显像剂摄取。
- 高CXCR4表达且PET阳性的复发患者,未来可能从[177Lu]Lu-Pentixather治疗中获益。
局限性
- 离体CXCR4表达与[68Ga]Ga-Pentixafor PET结果不能直接转化。
- PET评估仅纳入7例复发胶质母细胞瘤患者,样本量小。
- CXCR4表达与IDH/MGMT状态及生存无显著相关性,但未报告具体统计值。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: CXCR4 (over)expression is found in multiple human cancer types, while expression is low or absent in healthy tissue. In glioblastoma it is associated with a poor prognosis and more extensive infiltrative phenotype. CXCR4 can be targeted by the diagnostic PET agent [68Ga]Ga-Pentixafor and its therapeutic counterpart [177Lu]Lu-Pentixather. We aimed to investigate the expression of CXCR4 in glioblastoma tissue to further examine the potential of these PET agents. METHODS: CXCR4 mRNA expression was examined using the R2 genomics platform. Glioblastoma tissue cores were stained for CXCR4. CXCR4 staining in tumor cells was scored. Stained tissue components (cytoplasm and/or nuclei of the tumor cells and blood vessels) were documented. Clinical characteristics and information on IDH and MGMT promoter methylation status were collected. Seven pilot patients with recurrent glioblastoma underwent [68Ga]Ga-Pentixafor PET; residual resected tissue was stained for CXCR4. RESULTS: Two large mRNA datasets (N = 284; N = 540) were assesed. Of the 191 glioblastomas, 426 cores were analyzed using immunohistochemistry. Seventy-eight cores (23 tumors) were CXCR4 negative, while 18 cores (5 tumors) had both strong and extensive staining. The remaining 330 cores (163 tumors) showed a large inter- and intra-tumor variation for CXCR4 expression; also seen in the resected tissue of the seven pilot patients-not directly translatable to [68Ga]Ga-Pentixafor PET results. Both mRNA and immunohistochemical analysis showed CXCR4 negative normal brain tissue and no significant correlation between CXCR4 expression and IDH or MGMT status or survival. CONCLUSION: Using immunohistochemistry, high CXCR4 expression was found in a subset of glioblastomas as well as a large inter- and intra-tumor variation. Caution should be exercised in directly translating ex vivo CXCR4 expression to PET agent uptake. However, when high CXCR4 expression can be identified with [68Ga]Ga-Pentixafor, these patients might be good candidates for targeted radionuclide therapy with [177Lu]Lu-Pentixather in the future.
引用
- Jacobs SM, Wesseling P, de Keizer B, et al. CXCR4 expression in glioblastoma tissue and the potential for PET imaging and treatment with [68Ga]Ga-Pentixafor /[177Lu]Lu-Pentixather. Eur J Nucl Med Mol Imaging. 2021. PMID: 33550492. doi:10.1007/s00259-021-05196-4
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。